FDA Focus Will Be Phase IV Commitments Amidst "Safety Cloud," GSK Says
This article was originally published in The Pink Sheet Daily
In light of the current "safety cloud," FDA may have an increasing focus on Phase IV commitments, GlaxoSmithKline said
You may also be interested in...
FDA's seizure of Paxil CR threatens about 90% of GlaxoSmithKline's remaining Paxil franchise sales in the U.S
The House Energy & Commerce Committee has opened its investigation into the withdrawal of Vioxx with letters to FDA and Merck
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.